NASDAQ · FDMT

4D Molecular Therapeutics, Inc.

$10.07 -$0.31 (-2.99%) 1D After hours

Key Metrics

$542.63M
Market cap
P/E · TTM
$88.24M
Revenue · TTM
−$160.90M
Net income
EPS · TTM $-2.89
Dividend yield
Free cash flow
Beta · 1Y 1.89
EBITDA · TTM −$174.35M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 23
    The stock moved +11.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 23
  • Jun 5
    The stock moved -13.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$542.63M
Enterprise value
Shares outstanding52.3M
52-wk range$4.27 – $14.00
Avg volume · 20D567.0K
Net cash
Book value / share$8.11
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About 4D Molecular Therapeutics, Inc.
IPO dateDec 11, 2020
Employees196

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S6.15
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -203.5%
Net -182.3%
FCF
ROE / ROIC -33.4% · —

Financial Health

Current ratio9.34
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$361.96M

Cash Flow · TTM

Operating CF −$129.45M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

3.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings